Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.ppat.1009544 http://scihub22266oqcxt.onion/10.1371/journal.ppat.1009544 34265018!8282039!34265018     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+Pathog 2021 ; 17 (7): e1009544 Nephropedia Template TP {{tp|p=34265018|t=2021. Intranasal gene therapy to prevent infection by SARS-CoV-2 variants |pdf=|usr=}}{{34265018}} gab.com Text Intranasal gene therapy to prevent infection by SARS-CoV-2 variants JO: PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=34265018 #FOAvip SARS-CoV-2 variants have emerged with enhanced pathogenicity and transmissibility, and escape from pre-existing immunity, suggesting first-generation vaccines and monoclonal antibodies may now be less effective. Here we present an approach for preventing clinical sequelae and the spread of SARS-CoV-2 variants. First, we affinity matured an angiotensin-converting enzyme 2 (ACE2) decoy protein, achieving 1000-fold binding improvements that extend across a wide range of SARS-CoV-2 variants and distantly related, ACE2-dependent coronaviruses. Next, we demonstrated the expression of this decoy in proximal airway when delivered via intranasal administration of an AAV vector. This intervention significantly diminished clinical and pathologic consequences of SARS-CoV-2 challenge in a mouse model and achieved therapeutic levels of decoy expression at the surface of proximal airways when delivered intranasally to nonhuman primates. Importantly, this long-lasting, passive protection approach is applicable in vulnerable populations such as the elderly and immune-compromised that do not respond well to traditional vaccination. This approach could be useful in combating COVID-19 surges caused by SARS-CoV-2 variants and should be considered as a countermeasure to future pandemics caused by one of the many pre-emergent, ACE2-dependent CoVs that are poised for zoonosis. Twit Text FOAVip Intranasal gene therapy to prevent infection by SARS-CoV-2 variants ????PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=34265018 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34265018 #FOAvip English Wikipedia <ref>{{Cite pmid|34265018}}</ref> Intranasal gene therapy to prevent infection by SARS-CoV-2 variants #MMPMID34265018 Sims JJ; Greig JA; Michalson KT; Lian S; Martino RA; Meggersee R; Turner KB; Nambiar K; Dyer C; Hinderer C; Horiuchi M; Yan H; Huang X; Chen SJ; Wilson JM PLoS Pathog 2021[Jul]; 17 (7): e1009544 PMID34265018show ga SARS-CoV-2 variants have emerged with enhanced pathogenicity and transmissibility, and escape from pre-existing immunity, suggesting first-generation vaccines and monoclonal antibodies may now be less effective. Here we present an approach for preventing clinical sequelae and the spread of SARS-CoV-2 variants. First, we affinity matured an angiotensin-converting enzyme 2 (ACE2) decoy protein, achieving 1000-fold binding improvements that extend across a wide range of SARS-CoV-2 variants and distantly related, ACE2-dependent coronaviruses. Next, we demonstrated the expression of this decoy in proximal airway when delivered via intranasal administration of an AAV vector. This intervention significantly diminished clinical and pathologic consequences of SARS-CoV-2 challenge in a mouse model and achieved therapeutic levels of decoy expression at the surface of proximal airways when delivered intranasally to nonhuman primates. Importantly, this long-lasting, passive protection approach is applicable in vulnerable populations such as the elderly and immune-compromised that do not respond well to traditional vaccination. This approach could be useful in combating COVID-19 surges caused by SARS-CoV-2 variants and should be considered as a countermeasure to future pandemics caused by one of the many pre-emergent, ACE2-dependent CoVs that are poised for zoonosis. |*Angiotensin-Converting Enzyme 2/biosynthesis/genetics[MESH] |*COVID-19 Drug Treatment[MESH] |*Dependovirus[MESH] |*Genetic Therapy[MESH] |*Genetic Vectors[MESH] |*SARS-CoV-2/genetics/metabolism[MESH] |Administration, Intranasal[MESH] |Animals[MESH] |COVID-19/genetics/metabolism[MESH] |Humans[MESH] |Mice[MESH]Intranasal gene therapy to prevent infection by SARS-CoV-2 variants (epmc).pdf DeepDyve Pubget Overpricing